Immix Biopharma (IMMX) Notes Payables (2020 - 2022)

Immix Biopharma (IMMX) posted Notes Payables of $50000.0 for Q1 2022, little changed sequentially from $50000.0 in Q4 2021.

Immix Biopharma (IMMX) Notes Payables (2020 - 2022) Analysis & Trends

Immix Biopharma has reported Notes Payables for 3 years, with the latest figure at $50000.0 in Q1 2022.

Quarterly Notes Payables changed N/A year-over-year to $50000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $50000.0 (changed N/A YoY) and the FY2021 annual result came in at $50000.0, changed 0.0% from the prior year.
Notes Payables held at $50000.0 in Q1 2022 per IMMX's latest filing, from $50000.0 in the prior quarter.
Over five years, Notes Payables peaked at $50000.0 in Q4 2020 and troughed at $50000.0 in Q4 2020.
A 3-year average of $50000.0 and a median of $50000.0 in 2020 frame the typical range for Notes Payables.
The widest YoY moves for Notes Payables: up 0.0% in 2021, down 0.0% in 2021.
Over 3 years, Notes Payables stood at $50000.0 in 2020, then changed by 0.0% to $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022.
According to Business Quant data, Notes Payables over the past three periods registered $50000.0, $50000.0, and $50000.0 for Q1 2022, Q4 2021, and Q4 2020 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Immix Biopharma	784.75 Mn	784.75 Mn	-

Download Data